Hormonal
Subcutaneous semaglutide at a maintenance dose of 2.4 mg once weekly produces clinically significant weight loss (mean reduction ~14-16%) in non-diabetic adults with obesity or overweight, significantly outperforming placebo.
For non-diabetic adults with obesity or overweight, weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, achieving an average 15% body weight reduction. This is significantly better than placebo or other existing medications. Treatment involves a gradual dose increase over 16 weeks to minimize side effects, combined with a calorie-restricted diet and exercise. Patients should be aware that stopping the medication often leads to weight regain, suggesting it may be a long-term therapy.
The consolidated data from the literature in this systematic review endorses the use of semaglutide as a highly efficient weight-reducing agent... In contrast to other classes of weight loss agents, which have not exceeded 10% of initial body weight loss at chronic tolerable dose administration, GLP-1 agent semaglutide has shown 14.9% body weight reduction in clinical trials [6].
Why this rating
Based on a systematic review of 9 RCTs and 1 retrospective cohort study, with high-quality appraisal (Cochrane RoB 2.0 and NOS).
Source
Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations
Nazeefa Fatima et al. · Cureus · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →